Stock of the Day: Could Aradigm Corporation Change Direction After Today’s Huge Decline?

Stock of the Day: Could Aradigm Corporation Change Direction After Today's Huge Decline?

The stock of Aradigm Corporation (NASDAQ:ARDM) is a huge mover today! About 979,751 shares traded hands or 4470.16% up from the average. Aradigm Corporation (NASDAQ:ARDM) has risen 9.85% since April 28, 2016 and is uptrending. It has outperformed by 3.93% the S&P500.
The move comes after 9 months negative chart setup for the $34.20 million company. It was reported on Dec, 1 by Barchart.com. We have $2.09 PT which if reached, will make NASDAQ:ARDM worth $2.74M less.

Analysts await Aradigm Corporation (NASDAQ:ARDM) to report earnings on March, 21.

According to Zacks Investment Research, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.”

Insitutional Activity: The institutional sentiment decreased to 0.8 in Q2 2016. Its down 0.45, from 1.25 in 2016Q1. The ratio worsened, as 3 funds sold all Aradigm Corporation shares owned while 1 reduced positions. 3 funds bought stakes while 2 increased positions. They now own 5.45 million shares or 0.52% less from 5.48 million shares in 2016Q1.
Jacobs Levy Equity Mngmt accumulated 14,800 shares or 0% of the stock. Tower Cap Ltd Limited Liability Company (Trc) accumulated 0% or 747 shares. Livingston Gp Asset Mgmt (Operating As Southport Management), a Tennessee-based fund reported 1,000 shares. Great Point Ptnrs Llc has invested 1.26% of its portfolio in Aradigm Corporation (NASDAQ:ARDM). Deutsche Bank & Trust Ag reported 61,538 shares or 0% of all its holdings. Ladenburg Thalmann Fincl Ser Incorporated last reported 0% of its portfolio in the stock. Point72 Asset Management Limited Partnership has 320,585 shares for 0.01% of their US portfolio. First Eagle Ltd holds 0.04% or 3.85M shares in its portfolio. Focused Wealth Management last reported 0% of its portfolio in the stock. Blackrock Fund, a California-based fund reported 1,934 shares. Acadian Asset Mgmt Llc accumulated 1,584 shares or 0% of the stock. Blackrock Investment Management has 0% invested in the company for 1,598 shares. Bank Of America Corp De has 0% invested in the company for 28 shares. Fmr Ltd accumulated 168,740 shares or 0% of the stock. Goldman Sachs has invested 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM).

Insider Transactions: Since October 4, 2016, the stock had 0 insider purchases, and 1 insider sale for $2,859 net activity. The insider Froehlich Juergen Kurt sold 423 shares worth $2,859.

More important recent Aradigm Corporation (NASDAQ:ARDM) news were published by: Streetinsider.com which released: “Aradigm Corp. (ARDM) Announces Mixed Results from Two Pulmaquin Phase 3s in …” on December 01, 2016, also Marketwatch.com published article titled: “Aradigm Corp. NASDAQ: ARDM”, Businesswire.com published: “Aradigm Corporation Announces First Closing of Private Placement Offering of …” on April 26, 2016. More interesting news about Aradigm Corporation (NASDAQ:ARDM) was released by: Seekingalpha.com and their article: “6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity” with publication date: August 08, 2014.

ARDM Company Profile

Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Firm offers AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Firm is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Firm is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment